Nuclear Medicine AtlasInteractive atlas

Thallium-201²⁰¹Tl-chloride

A potassium analog with redistribution, legacy cardiac, viability, and tumor agent

Evidence B#cardiology#viability#legacy#SPECTUpdated 2026-07-27 · Physician-reviewed
High-yield mode — key points, high-yield facts, tables & quizzes only. Toggle off for full text.

Quick Answer

Thallium-201 is a potassium analog taken up by viable myocardium (and other cells) via the Na⁺/K⁺-ATPase, in proportion to blood flow. Its defining feature is redistribution: initial uptake reflects perfusion, but over hours thallium washes in and out so that viable-but-underperfused ("hibernating") myocardium fills in on delayed/reinjection imaging. Largely superseded by Tc-99m agents for routine perfusion (low-energy emissions, higher dose), it retains value for myocardial viability.

Mechanism

Active transport via the Na⁺/K⁺-ATPase (potassium analog); continuous exchange with the blood pool drives redistribution over ~3–24 h. Initial distribution tracks perfusion; the delayed distribution tracks viability (cell-membrane integrity), which is why a fixed early defect that later fills in indicates living, not scarred, tissue.

Biodistribution & Physics

Myocardium, skeletal muscle, kidneys, thyroid, and gut. The low-energy characteristic X-rays (69–80 keV) and 73-hour half-life mean higher radiation dose and poorer image quality/attenuation than Tc-99m (140 keV) — the principal reasons for its decline in routine MPI.

Clinical Indications

  • Myocardial viability: stress–redistribution–reinjection protocols; delayed fill-in indicates viable, hibernating myocardium.
  • Historic myocardial perfusion imaging (now mostly Tc-99m or PET).
  • Legacy parathyroid and brain-tumor imaging (now other agents).

Protocol Notes

  • Typical activity ~3–4 mCi; LEHR collimator; low-energy window (~70 keV X-rays ± 167 keV γ).
  • Stress → redistribution (3–4 h) → ± reinjection for viability; late (24 h) imaging in some protocols.
  • Because thallium redistributes, timing is intrinsic to interpretation (unlike sestamibi).

Interpretation Highlights

  • Redistribution/fill-in of a stress defect = viability; a persistent (fixed) defect that does not fill in after reinjection = scar.
  • Reverse redistribution (a defect that appears/worsens on delayed images) — variable significance (post-revascularization, artifact, or subendocardial injury).
  • Increased lung uptake — a marker of stress-induced LV dysfunction / high-risk disease.

Reporting Checklist

  • State the protocol (stress–redistribution–reinjection; delayed imaging).
  • Report fill-in vs fixed defects (viability), TID, and lung uptake (high-risk sign).
  • Note attenuation/low-count limitations of the low-energy emissions.

Common Pitfalls

  • Calling a fixed thallium defect "scar" without redistribution/reinjection imaging (underestimates viability).
  • Attenuation and low-count artifacts from the low-energy emissions.
  • Misreading reverse redistribution as significant without context.

Board Pearls

Thallium-201 is a potassium analog taken up by viable myocytes (Na⁺/K⁺-ATPase) in proportion to flow, and its defining feature is redistribution: initial uptake reflects perfusion, but delayed/reinjection imaging shows viable-but-hibernating myocardium filling in. Redistribution = viability — a fixed defect that fills in is viable, not scar.

Increased lung uptake on thallium is a high-risk marker (stress-induced LV dysfunction). Low-energy X-ray emissions (69–80 keV), a 73-h half-life, and higher dose (poorer images/attenuation than Tc-99m) explain why thallium is now a viability, not routine-perfusion, agent.

Interpretation depends on protocol and timing because thallium redistributes (unlike sestamibi's minimal redistribution). Beware reverse redistribution — a delayed defect of variable significance. Alternatives for viability include FDG-PET perfusion–metabolism mismatch (reference standard), Tc-99m gated wall-thickening, and CMR late-gadolinium transmurality.

  • Protocol: Myocardial viability; contrast tracer: sestamibi/tetrofosmin (minimal redistribution).
  • Related: Nuclear cardiology overview, MPI SPECT; pitfalls: Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

  • A redistribution time-course schematic (perfusion early → viability late).
  • A fill-in vs fixed defect teaching pair (viable vs scar).
  • A lung-uptake high-risk illustration.

Self-Check

Q1. What does redistribution of a stress thallium defect indicate?

Answer: Viability — a defect that fills in on delayed/reinjection imaging is viable (hibernating) myocardium, not scar.

Q2. Why has thallium been largely replaced by Tc-99m agents for routine perfusion?

Answer: Its low-energy X-rays (69–80 keV), long 73-h half-life, and higher radiation dose give poorer images/attenuation than Tc-99m (140 keV).

Q3. What does increased lung uptake on a thallium study signify?

Answer: A high-risk marker of stress-induced LV dysfunction.

Q4. A fixed thallium defect is called "scar" without reinjection imaging. What is the error?

Answer: It underestimates viability — a fixed early defect may fill in after reinjection/redistribution, indicating viable myocardium.

Evidence & sources

BASNC guidance on thallium-201 myocardial perfusion and viability (stress–redistribution–reinjection).
BViability meta-analysis — Allman KC, et al. J Am Coll Cardiol 2002.
Cite this page. Nuclear Medicine Atlas. “Thallium-201.” v1.76, 2026-10-25. Permalink: https://nuc.med/thallium-201/ Report an issue
Nuclear Medicine Atlas · v1.76 · built 2026-10-25Terms · Privacy · Disclaimer